Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talaporfin - Meiji Seika Pharma

Next Previous
Drug Profile

Talaporfin - Meiji Seika Pharma

Alternative Names: Aptocine; Laserphyrin; Leserfin; Litx; LS 11; ME-2906; Mono-L-aspartyl chlorin e6; MR 901; NP e6; NPE 6; Talaporfin sodium; Taporfin sodium

Latest Information Update: 13 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Light Sciences Oncology; Meiji Seika Pharma; The Childrens Hospital of Philadelphia
  • Class Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Porphyrins; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Oesophageal cancer; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glioma; Lung cancer; Oesophageal cancer
  • Preregistration Cervical intraepithelial neoplasia
  • Discontinued Age-related macular degeneration; Benign prostatic hyperplasia; Cardiovascular disorders; Colorectal cancer; Liver cancer; Neurofibromatosis 1; Prostate cancer

Most Recent Events

  • 13 Aug 2026 Preregistration for Cervical intraepithelial neoplasia in Japan (IV) (Meiji Seika Pharma pipeline, August 2026)
  • 30 Nov 2025 Efficacy and adverse events data from a phase II trial in Cervical intraepithelial neoplasia released by Meiji Seika Pharma
  • 01 Jul 2023 Meiji Seika Pharma completes a phase-II trial in Cervical intraepithelial neoplasia in Japan (IV) (jRCT2041190087)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top